跳至主要内容
临床试验/NCT02586584
NCT02586584Unknown不适用

The I-Score Study: The Development and Validation of a Patient-Reported Measure of Antiretroviral Therapy's Interference With Life: A Clinical Patient-management Tool for Healthcare Providers

Dr. Bertrand Lebouche1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2016年4月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
160
试验地点
1
主要终点
Change in the Interference-Score (I-Score)

研究概览

简要总结

The purpose of this Canada-France study is to develop and validate a multidimensional patient-reported measure of perceived barriers to antiretroviral therapy adherence for HIV-positive patients undergoing treatment that will be theoretically founded, easy to use and helpful to clinicians in their medical decision-making, in a clinical or research setting.

详细描述

This 24-month study aims to develop and validate a theoretically founded patient-reported outcome measure for use in routine HIV care with patients on antiretroviral therapy (ART). Eight clinical sites will be involved (4 in Canada and 4 in France). The measure will centre on patients' reported barriers to ART adherence and will be adapted for administration via electronic tablet. The study has four main steps. The psychometric validation of the tool and core of the study will be conducted in Step 3. The Observational -Prospective design applies to the field test and retest phase of Step 3. The four steps are nevertheless described below.

Step 1 -Development of the measure's conceptual framework (Start: October 2015)

  1. A scoping review of existing HIV-specific patient-reported outcome measures
  2. A meta-ethnography of qualitative research on HIV-positive persons' reported barriers to antiretroviral therapy (ART) adherence
  3. A content analysis of qualitative interviews with HIV-positive patients on ART about their perceived barriers to adherence (n = 30 patients) The meta-ethnography and content analysis will serve to develop the conceptual framework on which the tool will be based. It will not only define the tool's conceptual domain but outline its relationship to other concepts that will be verified statistically as a part of the tool's validation. Once the framework is completed, the measure will be specified and a bank of items will be generated.

Step 2 -Linguistic validation of the preliminary measure The tool's linguistic validation will involve the professional harmonization of the English and French versions and the creation of a universal French version adapted to all French sites.

Step 3 - Exploration and validation of the measure's psychometric properties

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be a man, woman or transgender person aged 18 years or older
  • Be diagnosed HIV-1 positive
  • Be treated by a combination of 2 to 3 antiretroviral drugs for at least 3 months
  • Ability to speak and understand either French or English

排除标准

  • Participation in a clinical trial at the time of enrollment in this study, in some cases (to be discussed on a site-by-site basis by the scientific committee)
  • Having a cognitive impairment or medical instability that prevents their use of the electronic tablet, completion of the questionnaire or participation in the interview
  • Insufficient mastery of French or English to complete the questionnaires or participate in the interview
  • Refusal to use the electronic tablet to fill out the questionnaire material (not relevant for the qualitative and cognitive interviews)
  • Co-infection with hepatitis C and currently under treatment for it or having completed hepatitis C treatment 3 months ago or less
  • Co-infection with hepatitis B and either not being treated for it or receiving a treatment for it other than one's antiretroviral therapy for HIV
  • Participation in the study's Pilot phase (for the field test and retest)

结局指标

主要结局

Change in the Interference-Score (I-Score)

时间窗: During the field test of Step 3 of the study, the I-Score will be administered at week 0 and then at week 4 to evaluate change (reliability)

The I-Score is the measure to be developed and concerns perceived barriers to antiretroviral therapy adherence

次要结局

未报告次要终点

研究者

发起方
Dr. Bertrand Lebouche
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Dr. Bertrand Lebouche

MD, PhD, Assistant Professor

McGill University Health Centre/Research Institute of the McGill University Health Centre

研究点 (1)

Loading locations...

相似试验

The I-Score Study: Developing a New Patient-Reported... | 临床试验